Logo
Log in
Subscribe
Logo
Type 1 Diabetes Weekly

Type 1 Diabetes Weekly

A weekly curated digest of the most significant Type 1 diabetes research, treatments, and innovations, focusing on scientific advancements, medical technologies, and global approaches to care. Each issue delivers concise summaries of cutting-edge studies, emerging therapies, and real-world patient experiences with direct links to explore further.

#74 - 🧬 Can IL-2 retrain the immune system?

Oct 6, 2026

•

5 min read

#74 - 🧬 Can IL-2 retrain the immune system?

Tregs, teplizumab, and what's next in T1D

Ian L.
Ian L.
#73 - Retogatein bought 5+ years ⏳

Sep 29, 2026

•

5 min read

#73 - Retogatein bought 5+ years ⏳

A delay before insulin, and what's next

Ian L.
Ian L.
#72 - Kerendia clears the FDA for T1D 💊

Sep 22, 2026

•

4 min read

#72 - Kerendia clears the FDA for T1D 💊

The first new kidney option in 30 years

Ian L.
Ian L.
#71 - 🩸 Screening kids for T1D at age 2

Sep 15, 2026

•

4 min read

#71 - 🩸 Screening kids for T1D at age 2

New global guidance on catching T1D early

Ian L.
Ian L.
#70 - Pivot pump gets a green light 🩸

Sep 8, 2026

•

4 min read

#70 - Pivot pump gets a green light 🩸

Plus a dual ketone monitor and faster insulin

Ian L.
Ian L.
#69 - The hypoglycemia gap in GLP-1 trials 🩸

Sep 1, 2026

•

5 min read

#69 - The hypoglycemia gap in GLP-1 trials 🩸

What T1D add-on studies aren't telling you

Ian L.
Ian L.
Load more

Type 1 Diabetes Weekly

A weekly curated digest of the most significant Type 1 diabetes research, treatments, and innovations, focusing on scientific advancements, medical technologies, and global approaches to care. Each issue delivers concise summaries of cutting-edge studies, emerging therapies, and real-world patient experiences with direct links to explore further.

© 2026 Data Drift Press.
beehiivPowered by beehiiv